立方体治疗对膝关节关节炎有有益影响吗?
Abla El Hajjaji1, Nessrine Akasbi1, Imane El Mezouar1
1Rheumatology, Hassan II University Hospital, Faculty of Medicine, Pharmacy and Dental Medicine, Sidi Mohamed Ben Abdellah University, Fez, MAR.
Cureus
|March 25, 2025
概括
药物可以改善膝关节骨关节炎 (KO) 疼痛. 这项研究发现,与不服用他类药物的患者相比,他类药物治疗与KO患者的临床改善有显著的关联.
科学领域:
- 类风湿病学 类风湿病学
- 心脏病学 心脏病学
- 公共卫生 公共卫生
背景情况:
- 膝关节关节炎 (KO) 显著影响生活质量.
- 脱脂症是一种与KO发生率和进展相关的并发症.
- 用于失脂症的他类药物可以减轻KO的进展.
研究的目的:
- 评估他类药物治疗对膝关节骨关节炎临床改善的影响.
- 用视觉模拟尺度 (VAS) 评估KO患者的疼痛减轻.
主要方法:
- 在465名膝关节骨关节炎患者 (2018年1月至2024年1月) 的回顾性,横截面研究中.
- 患者分为他类药物治疗组 (n=48) 和对照组 (n=417).
- 主要结局:用视觉模拟尺度 (VAS) 测量疼痛的临床改善.
主要成果:
- 在接受他类药物治疗的患者中,有70.8%的患者出现显著的临床改善,对照组为47.1% (p=0.001).
- 静止剂的使用独立地与膝关节骨关节炎的临床改善有关.
- 类他类药物与减少疼痛强度有着显著的关联.
结论:
- 达丁类药物治疗可能有助于控制膝关节骨关节炎的疼痛.
- 结果表明,他类药物可以作为常规KO治疗的辅助剂.
- 需要进一步的前性研究来阐明KO中的他类药物机制.
更多相关视频
07:22Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
Published on: March 7, 2025
155
04:57Author Spotlight: Minimally Invasive Ultrasound-Guided Acupotomy in Knee Osteoarthritis Treatment
Published on: April 26, 2024
421
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
484
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
484
The JAK-STAT Signaling Pathway
8.6K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.6K
